Diagnosis, Treatment and Outcome of Gestational Trophoblastic Neoplasia in a Low Resource Income Country

Background and Introduction: Gestational trophoblastic disease (GTD) is a disease of the proliferative trophoblastic allograft. Diagnosis and treatment of GTN in low resource-income countries is challenging due to numerous factors. The objective of this study was to review outcomes of gestational trophoblastic neoplasia in women of low socioeconomic status with limited resources and social support. Methods: This study was performed at Gynecologic and Obstetric Clinic of Dakar Teaching Hospital, the reference Centre of Gestational trophoblastic diseases in Senegal from 2006 to 2015. Results: Out of 1088 patients followed for gestational trophoblastic disease during the study period, 108 patients were diagnosed and treated for GTN: 88 low-risk and 20 high-risk. Low-risk patients received an average of 6.9 cycles of initial single-agent chemotherapy. Twelve patients had persistent disease and were switched to a second line multi-agent chemotherapy. Finally 94.3% of low-risk patients achieved remission. All high-risk patients were initially treated with multi-agent chemotherapy, averaging 7 cycles. Five of the eighty-eight low-risk patients and twelve of the 20 high-risk patients died of disease. Conclusion and Global Health Implications: Early adequate treatment ensures an excellent prognosis for patients with GTN. In low-income countries, difficulties encountered in diagnosis and treatments worsen the prognosis of GTN patients. Clinical trials are needed to find out affordable schedules or drugs for a better treatment.

[1]  T. Lawrie,et al.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.

[2]  R. Berkowitz,et al.  Diagnosis, classification and treatment of gestational trophoblastic neoplasia. , 2015, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.

[3]  N. Sebire,et al.  Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  R. Berkowitz,et al.  Current management of gestational trophoblastic neoplasia. , 2012, Hematology/oncology clinics of North America.

[5]  R. Berkowitz,et al.  Current management of gestational trophoblastic diseases. , 2009, Gynecologic oncology.

[6]  P. Maisonneuve,et al.  Gestational Trophoblastic Neoplasia , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[7]  M. Toure,et al.  Prévention du choriocarcinome postmôlaire en milieu Africain : exemple du sénégal , 2005 .

[8]  FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. , 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[9]  L C Chesley,et al.  American Journal of Obstetrics and Gynecology, Volume 124, 1976: The remote prognosis of eclamptic women. Sixth periodic report. , 2000, American journal of obstetrics and gynecology.

[10]  S. Goldman,et al.  Hematology/Oncology Clinics of North America , 2020, Hematology/Oncology Clinics of North America.